Glucose metabolism in immune cells

Glucose metabolism shapes immune cell fate,driving effector responses through glycolysis while sustaining memory, regulatory, and repair functions through mitochondrial oxidation.

Glucose metabolism is a central regulator of immune cell fate, dictating whether cells remain quiescent, mount rapid effector responses, or adopt regulatory and memory states.

Beyond ATP supply, glycolysis and mitochondrial oxidation regulate biosynthesis, redox balance, and signaling through nodes such as mTORC1, HIF-1α, and c-Myc.

The metabolic logic of immune activation

Resting immune cells generally rely on oxidative phosphorylation (OXPHOS) and fatty acid oxidation (FAO) to meet low, steady ATP demands efficiently.

When activated, many immune cells shift toward aerobic glycolysis, the Warburg effect, converting glucose to lactate even when oxygen is available. This shift sacrifices ATP yield for speed and biosynthetic flexibility.¹,²

The rationale is functional. Rapid glycolytic flux supplies carbon for the pentose phosphate pathway (PPP), producing NADPH for reactive oxygen species (ROS) and biosynthesis, as well as ribose for nucleotide synthesis. Glycolytic intermediates also feed serine, glycine, and amino sugar pathways required for proliferation, cytokine production, and effector function.²,³

Core regulators of immune glucose metabolism

A conserved set of transporters, enzymes, and signaling hubs coordinates immune glycolytic programming:

GLUT1 and GLUT3: glucose transporters upregulated during lymphocyte and myeloid activation to meet nutrient demand.⁴

Hexokinases (HK1, HK2): catalyze the first committed step of glycolysis; HK2 is often inducible during activation.

PKM2 and LDH: regulate glycolytic flux and lactate generation; PKM2 also participates in HIF-1α–linked inflammatory transcription in macrophages.⁵

GAPDH: a glycolytic enzyme with moonlighting RNA-binding activity that couples glycolytic flux to cytokine mRNA translation in T cells.³

mTORC1 and c-Myc: anabolic hubs that drive glucose uptake, glycolysis, and biomass accumulation after activation.¹

HIF-1α: links inflammatory and hypoxic signals to glycolytic gene expression and IL-1β production.⁵,⁶

AMPK: a low-energy sensor that favors catabolic OXPHOS and FAO programs, restraining glycolytic bias.
Together, these nodes convert extracellular activation signals into a coordinated metabolic state that supports the required immune function.

Glucose metabolism in macrophages

Macrophage metabolism illustrates how polarization and function are linked to fuel choice. Pro-inflammatory (M1-like) macrophages, activated by lipopolysaccharide (LPS) and IFN-γ, increase glucose uptake, glycolysis, PPP activity, and lactate production. TCA-cycle remodeling leads to succinate accumulation, which stabilizes HIF-1α and amplifies IL-1β transcription.⁶,⁷

The PPP is particularly important because it provides NADPH for nitric oxide and ROS generation, directly enabling antimicrobial killing. Itaconate, derived from the TCA-cycle intermediate cis-aconitate, acts as a negative-feedback metabolite that inhibits succinate dehydrogenase and dampens excessive inflammation.⁸

By contrast, anti-inflammatory (M2-like) macrophages associated with tissue repair typically rely on OXPHOS and FAO. However, the M1/M2 metabolic dichotomy is a simplification: many M2-associated programs retain glycolytic activity, and macrophage metabolism ultimately depends on stimulus, tissue niche, and disease context.⁷

Glucose metabolism in T cells

Naive T cells are metabolically quiescent, relying on OXPHOS and FAO. T-cell receptor engagement combined with co-stimulation activates PI3K–Akt–mTORC1 and c-Myc, driving GLUT1/GLUT3 expression and a strong glycolytic shift that supports clonal expansion and effector differentiation.¹

Glycolysis is not only an energy strategy but also a direct regulator of cytokine output. Aerobic glycolysis releases GAPDH from binding IFN-γ mRNA, permitting translation of this key effector cytokine, a clear example of metabolic control of immune function.³

HIF-1α and pyruvate dehydrogenase kinase 1 (PDHK1) shape the Th17–Treg balance by favoring glycolytic, inflammatory programs over oxidative, regulatory ones.⁹ Enhancing mitochondrial FAO, in turn, supports CD8+ memory formation.¹⁰

Glucose metabolism in B cells

Resting B cells have modest metabolic demands, but B-cell receptor engagement and co-stimulation increase glucose uptake, glycolysis, mitochondrial mass, and OXPHOS in parallel.¹¹ Unlike T cells, activated B cells do not favor glycolysis alone; balanced glycolytic and oxidative metabolism supports clonal expansion, class switching, and antibody secretion.

Germinal center B cells also engage FAO and glutamine metabolism, reflecting the biosynthetic demands of high-rate immunoglobulin production. In B-cell malignancies, glycolysis and glutaminolysis are frequently dysregulated, positioning these pathways as therapeutic vulnerabilities in a subtype-dependent manner.

How does glucose metabolism shape innate immune cells?

Innate immune cells couple glycolytic flexibility to rapid effector responses. Neutrophils rely predominantly on glycolysis at baseline because of low mitochondrial density, enabling fast ATP generation for chemotaxis, phagocytosis, degranulation, and oxidative burst. FAO can substitute under glucose limitation but is not their primary fuel.

Dendritic cells (DCs) undergo a rapid glycolytic shift after Toll-like receptor (TLR) engagement, supporting maturation, cytokine production, and migration to lymph nodes.¹² HIF-1α reinforces this program in inflamed or hypoxic tissues, though DC metabolism remains stimulus-dependent — some contexts favor sustained OXPHOS and FAO.

Natural killer (NK) cells transition from OXPHOS at rest to mTORC1-driven glycolysis upon cytokine or receptor activation, which is required for full cytotoxicity and IFN-γ production. Nutrient competition and lactate accumulation in tumors can blunt this program and impair NK effector function.

How does the tumor microenvironment reshape immune glucose metabolism?

Tumors reshape immune metabolism by creating a glucose-poor, lactate-rich, and often hypoxic microenvironment. Highly glycolytic tumor cells outcompete tumor-infiltrating T cells for glucose, restricting glycolytic effector programs and impairing cytokine production and cytotoxicity.¹³

Tumor-derived lactate compounds this suppression. Extracellular lactate directly inhibits T-cell and NK-cell function and promotes M2-like polarization of tumor-associated macrophages, reinforcing an immunosuppressive niche.¹⁴ PD-1 signaling further suppresses T-cell glycolysis and shifts metabolism toward lipid oxidation, linking checkpoint biology to nutrient use and providing a rationale for combining checkpoint blockade with metabolic strategies.

How does immunometabolism contribute to autoimmune and metabolic disease?

Autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis are marked by exaggerated glycolytic and anabolic programming in pathogenic T cells and macrophages. Elevated mTOR/HIF-1α signaling, GLUT1 expression, and PDHK1 activity skew CD4+ T cells toward Th17 responses at the expense of Treg function.⁹ Persistent lactate and cytokine-rich environments sustain chronic inflammation and tissue injury.

In obesity, type 2 diabetes, and non-alcoholic fatty liver disease, chronic nutrient excess drives infiltration of glycolytic, M1-like macrophages into adipose tissue and liver, where they release IL-1β and TNF-α and promote insulin resistance.

T cells in these tissues skew toward Th1 and Th17 phenotypes, amplifying low-grade inflammation. NAMPT (also known as visfatin) links NAD-salvage metabolism to inflammatory adipokine signaling and has been implicated in both autoimmune and metabolic dysfunction, though it is best understood as an NAD-pathway regulator rather than a direct glycolytic enzyme.

FAQs

Why do activated immune cells use aerobic glycolysis if OXPHOS produces more ATP?

Aerobic glycolysis prioritizes speed and biosynthesis over ATP yield. Glycolytic intermediates feed the PPP, nucleotide synthesis, and amino acid pathways required for proliferation and cytokine production, while lactate regeneration of NAD+ sustains high flux.²,³

Do all activated immune cells rely on glycolysis?

No. Tregs, memory T cells, and many M2-like macrophages preferentially use OXPHOS and FAO. Even within "glycolytic" subsets, mitochondrial metabolism remains essential for redox balance, biosynthesis, and long-term fitness.¹,¹⁰